{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:44:09Z","timestamp":1783950249253,"version":"3.55.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined. We present post hoc data on urinary 5-HIAA and plasma chromogranin A (CgA) from the CLARINET study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot\/autogel 120 mg or placebo once every 28 days for 96 weeks. Tumor response, evaluated centrally (RECIST 1.0), and progression-free survival (PFS) were assessed by treatment and biochemical response, defined as (a) baseline &amp;gt;upper limit of normal (ULN, 41.6 \u03bcmol per day 5-HIAA; 98.1 \u03bcg\/L CgA) and (b) \u226550% decrease from baseline and to \u2264ULN value on study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-eight percent (82 of 171; lanreotide, n = 45; placebo, n = 37) and 66% (129 of 195; lanreotide, n = 65; placebo, n = 64) of randomized patients had 5-HIAA and CgA &amp;gt; ULN at baseline. Among patients with &amp;gt;ULN baseline values who did not progress after 96 weeks of treatment, significantly greater reductions in 5-HIAA and CgA were observed in lanreotide-treated versus placebo-treated patients throughout the study (all p &amp;lt; .05). PFS was significantly prolonged among 5-HIAA responders versus nonresponders (median not reached vs. 16.2 months, p &amp;lt; .0001; hazard ratio [HR] = 0.21, 95% confidence interval [CI], 0.09\u20130.48) and CgA responders versus nonresponders (median not reached vs. 16.2 months, p = .0070; HR = 0.30, 95% CI, 0.12\u20130.76), regardless of treatment arm. PFS was also significantly prolonged among lanreotide-treated 5-HIAA responders versus nonresponders (p = .0071) but was not significantly different among placebo-treated 5-HIAA responders versus nonresponders. There were no significant differences in PFS between lanreotide-treated CgA responders versus nonresponders or between placebo-treated CgA responders versus nonresponders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The 5-HIAA findings are noteworthy because they occurred in patients with nonfunctioning enteropancreatic neuroendocrine tumors. Monitoring 5-HIAA and CgA may be useful when treating patients with nonfunctional neuroendocrine tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Current guidelines focus only on the monitoring of 5-hydroxyindoleacetic acid (5-HIAA) in the diagnosis and management of functional neuroendocrine tumors with carcinoid syndrome. The current post hoc analysis of patients with nonfunctional enteropancreatic neuroendocrine tumors in the CLARINET study demonstrated that measuring and following both 5-HIAA and chromogranin A as biomarkers of disease progression may be useful in the management of patients with nonfunctional neuroendocrine tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0217","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T16:33:29Z","timestamp":1540398809000},"page":"463-474","source":"Crossref","is-referenced-by-count":15,"title":["Effect of Lanreotide Depot\/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors"],"prefix":"10.1093","volume":"24","author":[{"given":"Marianne E.","family":"Pavel","sequence":"first","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin, Berlin, Germany"},{"name":"Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria T.","family":"Phan","sequence":"additional","affiliation":[{"name":"University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Wolin","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beloo","family":"Mirakhur","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilani","family":"Liyanage","sequence":"additional","affiliation":[{"name":"Ipsen, Les Ulis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pitman Lowenthal","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"George A.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron I.","family":"Vinik","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of CLARINET Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"2021122506315853600_onco12714-bib-0001","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122506315853600_onco12714-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","article-title":"The epidemiology of gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2021122506315853600_onco12714-bib-0003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2021122506315853600_onco12714-bib-0004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","article-title":"Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)","volume":"26","author":"Kanakis","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2021122506315853600_onco12714-bib-0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000368363","article-title":"Neuroendocrine tumor biomarkers: Current status and perspectives","volume":"100","author":"Modlin","year":"2014","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0006","first-page":"115","article-title":"Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide","volume":"21","author":"Kos-Kud\u0142a","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"key":"2021122506315853600_onco12714-bib-0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000381715","article-title":"Impact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: Analysis from the phase III RADIANT-2 trial","volume":"102","author":"Anthony","year":"2015","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"suppl 3","key":"2021122506315853600_onco12714-bib-0009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/jco.2014.32.3_suppl.268","article-title":"ELECT: A phase 3 study of efficacy and safety of lanreotide autogel\/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)","volume":"32","author":"Vinik","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122506315853600_onco12714-bib-0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: Res1ults from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122506315853600_onco12714-bib-0012","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","article-title":"Risk factors for the development and progression of carcinoid heart disease","volume":"107","author":"Bhattacharyya","year":"2011","journal-title":"Am J Cardiol"},{"key":"2021122506315853600_onco12714-bib-0013","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122506315853600_onco12714-bib-0014","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","article-title":"Discriminating capacity of indole markers in the diagnosis of carcinoid tumors","volume":"46","author":"Meijer","year":"2000","journal-title":"Clin Chem"},{"key":"2021122506315853600_onco12714-bib-0015","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"key":"2021122506315853600_onco12714-bib-0016","author":"National Comprehensive Cancer Network","year":"2017"},{"key":"2021122506315853600_onco12714-bib-0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0004563213489670","article-title":"The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia","volume":"51","author":"Bech","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"2021122506315853600_onco12714-bib-0018","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"2021122506315853600_onco12714-bib-0019","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/jco.2016.34.4_suppl.434","article-title":"Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"34","author":"Phan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122506315853600_onco12714-bib-0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2021122506315853600_onco12714-bib-0021","author":"Phan","year":"2017"},{"key":"2021122506315853600_onco12714-bib-0022","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1208\/s12248-016-9884-3","article-title":"Establishing the quantitative relationship between lanreotide autogel, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors","volume":"18","author":"Buil-Bruna","year":"2016","journal-title":"AAPS J"},{"key":"2021122506315853600_onco12714-bib-0023","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122506315853600_onco12714-bib-0024","author":"Cisbio Bioassays. Chromogranin A"},{"key":"2021122506315853600_onco12714-bib-0025","doi-asserted-by":"crossref","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: Past, present and future","volume":"23","author":"Oberg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2021122506315853600_onco12714-bib-0026","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s11605-007-0263-3","article-title":"Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: Analysis of 9,821 patients","volume":"11","author":"Bilimoria","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"2021122506315853600_onco12714-bib-0027","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/MPA.0b013e31822041a9","article-title":"Serotonin-producing enterochromaffin cell tumors of the pancreas: Clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors","volume":"40","author":"La Rosa","year":"2011","journal-title":"Pancreas"},{"key":"2021122506315853600_onco12714-bib-0028","doi-asserted-by":"crossref","first-page":"6564A","DOI":"10.1016\/S0959-8049(11)71875-5","article-title":"Correlation of PFS with early response of chromogranin a and 5-hydroxyindoleacetic acid levels in PTS with advanced neuroendocrine tumours: Phase III radiant-2 study results","volume":"47","author":"Baudin","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122506315853600_onco12714-bib-0029","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122506315853600_onco12714-bib-0030","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122506315853600_onco12714-bib-0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122506315853600_onco12714-bib-0032","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","article-title":"The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract","volume":"96","author":"Formica","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122506315853600_onco12714-bib-0033","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.ejca.2007.07.025","article-title":"Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours","volume":"43","author":"van der Horst-Schrivers","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122506315853600_onco12714-bib-0034","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/EJE-16-0392","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","author":"Zandee","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2021122506315853600_onco12714-bib-0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"2021122506315853600_onco12714-bib-0036","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0037","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1097\/MD.0000000000000247","article-title":"Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2021122506315853600_onco12714-bib-0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00365521.2012.733953","article-title":"Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors","volume":"48","author":"Jensen","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2021122506315853600_onco12714-bib-0039","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced PNET treated with everolimus","volume":"96","author":"Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122506315853600_onco12714-bib-0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000162876","article-title":"Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors","volume":"89","author":"Korse","year":"2009","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0041","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000369818","article-title":"Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: A large series from a single institution","volume":"100","author":"Massironi","year":"2014","journal-title":"Neuroendocrinology"},{"key":"2021122506315853600_onco12714-bib-0042","first-page":"1027","article-title":"Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids","volume":"25","author":"Manf\u00e9","year":"2011","journal-title":"In Vivo"},{"key":"2021122506315853600_onco12714-bib-0043","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/egh.12.15","article-title":"Chromogranin A: A sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors","volume":"6","author":"Singh","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2021122506315853600_onco12714-bib-0044","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"Arnold","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122506315853600_onco12714-bib-0045","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-011-1862-5","article-title":"Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour","volume":"38","author":"Fiebrich","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021122506315853600_onco12714-bib-0046","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/clinchem\/38.9.1730","article-title":"Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites","volume":"38","author":"Kema","year":"1992","journal-title":"Clin Chem"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/4\/463\/41917452\/oncolo_24_4_463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/4\/463\/41917452\/oncolo_24_4_463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:32:45Z","timestamp":1640413965000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/4\/463\/6439176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,10,24]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0217","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,1]]},"published":{"date-parts":[[2018,10,24]]}}}